Chimerix (CMRX) Shares are Up 16.81%

Chimerix (CMRX) : Traders are bullish on Chimerix (CMRX) as it has outperformed the S&P 500 by a wide margin of 31.67% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 16.19%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 16.81% in the last 1 week, and is up 29% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 17.82% and the 50-Day Moving Average is 27.23%.The 200 Day SMA reached 31.47% Chimerix, Inc. is up 49.46% in the last 3-month period. Year-to-Date the stock performance stands at -37.88%.


Chimerix (CMRX) : Currently there are 7 street experts covering Chimerix (CMRX) stock. The most bullish and bearish price target for the stock is $12 and $5 respectively for the short term. The average price target of all the analysts comes to $7.29. The estimated standard deviation from the target is $2.29.

Company shares have received an average consensus rating of Hold for the current week Chimerix (NASDAQ:CMRX): The stock opened at $5.25 and touched an intraday high of $5.59 on Friday. During the day, the stock corrected to an intraday low of $5.11, however, the bulls stepped in and pushed the price higher to close in the green at $5.56 with a gain of 6.51% for the day. The total traded volume for the day was 1,402,435. The stock had closed at $5.56 in the previous trading session.

Chimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Companys lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.